Pfizer announces Phase 3 clinical trial for vaccine against Respiratory Syncytial Virus (RSV)
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
The segment delivered strong sales growth of 20% YoY
Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).
Subscribe To Our Newsletter & Stay Updated